NCT01853956View on ClinicalTrials.gov

Bioequivalence Trial of Alprazolam 0.25 mg Tablets

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

December 2, 2010

Primary Completion Date

December 10, 2010

Study Completion Date

December 10, 2010

Conditions

Anxiety Disorders

Interventions

DRUG

Alprazolam 0.25 mg

Reference product

DRUG

Alprazolam 0.25 mg

Test product

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY